Mina Maher Raouf
Minya, 61511, Egypt
NCT Number: NCT06612307
Leucocyte subpopulation and platelet indices analysis can predict clinical outcome
Looking for future studies?
Notify Me18 year–70 year
All sexes
Observational
Minya, 61511, Egypt
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: from biomarker sampling through fifth calendar day
SOFA increase 2 points or more, or development of septic shock, or mortality. leukocyte profile versus platelet indices. Early deterioration was defined as any of the above mentioned events occurring for the first time from T0 until (through) second calendar day. T0 was the biomarker sampling immediately after sepsis diagnosis. Timing of deterioration was subclassified from To to second calendar day ( any deterioration events for the first time from T0 until second calendar day after that defined as very early deterioration) or early deterioration ( from third calendar day to day-5 = any deterioration events occur for the first time only from third to the fifth calendar day inclusive after T0
Time frame: 2 weeks ( during ICU admission)
Time frame: 2 weeks (during ICU admission)
Time frame: 2 weeks
Time frame: 2 weeks (during ICU admission)
Time frame: 2 weeks (during ICU admission)
Time frame: 2 weeks (during ICU admission )
Minia University
Other
Sensitivity and Specificity of Leucocytes Subpopulation Versus Platelet Indices in Prediction of Clinical Outcome for Candidates With Sepsis. A Bi-centric Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06541600
Infections, Inflammation
Wuhan, Hubei, China
View Trial DetailsNCT06080282
Infections, Inflammation
Wuhan, Hubei, China
View Trial DetailsNCT07025096
Acute Respiratory Distress Syndrome (ARDS), Infections
Philadelphia, Pennsylvania, United States
View Trial DetailsNCT06876168
Acute Respiratory Failure, Infections
Lexington, Kentucky, United States
View Trial Details